Application and Effectiveness Analysis of Community-Based Diabetes Prevention Program in Korea
- Conditions
- Endocrine, nutritional and metabolic disease
- Registration Number
- KCT0001981
- Lead Sponsor
- The Catholic University of Korea
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 420
Adults 30-64 years
-Body mass index (BMI) = 23 kg/m2
-Impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) according to the criteria of the World Health Organization (WHO)
- Subjects who diagnosed with diabetes mellitus
· Fasting plasma glucose (FPG) = 126 mg/dL or HbA1c = 6.5%
· 2-h plasma glucose (PG) = 200 mg/dL based on 75-g OGTT
- Subjects who previously admitted for cardiovascular disease within 6 months
- Subjects who had a history of aortic stenosis, left bundle block or third degree atrioventricular block or who had a pacemaker
- Subjects who previously diagnosed with renal disease (creatinine = 1.4 mg/dl in men, or = 1.3 mg/dl in women)
- Subjects who previously diagnosed with malignant disease within 5 years
- Subjects who have anemia (hematocrit < 36 % in men or < 33 % in women)
- Subjects who have hepatitis or liver cirrhosis
- Subjects who have acute gastrointestinal disease
- Subjects who have a plan of surgery in 3-6 months
- Subjects who have chronic infection (human immunodeficiency virus, tuberculosis, etc.)
- Subjects with pulmonary disease, who need supplemental oxygen or bronchodilator therapy
- Subjects who cannot communicate effectively in Korean
- Subjects who do not want to receive any kind of intervention.
- Subjects who are pregnant or had delivery within 3 months or have a plan of pregnancy
- Subjects who have major psychiatric disease or heavy alcoholics
- Subjects who cannot walk 400 meters in 10 minutes
- Subjects who participate in different clinical studies or may not understand this study process.
- Subjects who had taken drugs or were clinical state described below
· Niacin, Glucocorticoids
· Selective serotonin re-uptake inhibitors in weight-reduction dose
· Other weight-loss medications
· Untreated thyroid disease or cushing's syndrome, acromegaly
· Fasting triglyceride level > 600 mg/dl despite therapy
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Development of new diabetes mellitus
- Secondary Outcome Measures
Name Time Method Diatary intake;Physical activity;Quality of life;Physical strength